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Etanercept, adalimumab, infliximab, and usteki-
numab are all biologic therapies licensed for the
treatment of chronic plaque psoriasis in the United
Kingdom. Although these therapies have advanced
the treatment of psoriasis, they can lose effectiveness
with time.1
Three studies looked at drug survival in partic-
ular.2-4 Warren et al2 found that in biologic-na€ıve
patients, negative predictors of drug survival were
female sex, being a current smoker, having a higher
baseline Dermatology Life Quality Index (DLQI),
and taking etanercept or infliximab. Positive predic-
tive factors were having psoriatic arthritis and taking
ustekinumab. A model for discontinuation because
of ineffectiveness found that one of the predictors for
discontinuation is a bodymass index greater than 35.
Warren et al2 found that survival with biologic
therapies decreases over time—77% in the first
year, 63% in the second year, and 53% in the third
year. Interestingly, ustekinumab had the highest
survival rate compared with all the other antietumor
necrosis factor inhibitors.
Gniadecki et al4 analyzed data derived from the
Danish biologics national registry. Etanercept was
found to have the shortest drug survival compared
with ustekinumab, which had the longest long-term
survival. A total of 81.9% of patients on ustekinumab,
as a first biologic, still remained on this therapy
4 years later, and when all patients, biologic na€ıve
and nonna€ıve, were included, this percentage
decreased to 70% at 4 years.3
One possible mechanism in which biologics lose
their efficacy is the presence of antidrug antibodiesthe Royal Liverpool and Broadgreen Hospitals NHS Trust.
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m.(ADA).5 Biologic therapies include fusion proteins
and monoclonal antibodies. Monoclonal antibodies
can either be murine, chimeric, or fully human. Mono-
clonal antibodies generate variable immunogenic re-
sponses and ADA depending on their type with the
fully humanized being the least immunogenic.6,7
METHODS
We undertook a retrospective survey of all patients
who took concomitant immunosuppressive agents
while taking ustekinumab for psoriasis from October
2009 toApril 2015 in anattempt to improve thebiologic
drug survival at the first indication of loss of efficacy.
A total of 76 patients were treated with ustekinumab
during this period, and 7 patients were identified who
required additional immunosuppression in the form
of methotrexate, fumaric acid esters, azathioprine,
hydroxyurea, and acitretin. All 7 patients had chronic
plaque psoriasis, and 2 had psoriatic arthritis.
RESULTS
Patients 1 through 7 are detailed in Table I. These
patients had concomitant immunosuppressive
agents with ustekinumab—2 women and 5 men.
Two patients took methotrexate, 1 took fumaric acid
esters, 3 took hydroxyurea, and 1 took azathioprine.
Three patients were biologic na€ıve and 4 wereJAAD Case Reports 2016;2:310-4.
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Table I. Seven patients who required additional immunosuppression while taking ustekinumab
Sex Age, y
Body
mass
index
Previous
systemic
treatment
Previous
biologic
treatment
PASI/DLQI
before
ustekinumab
PASI and
DLQI
at wk 16
Duration between
start of ustekinumab
and additional
immunosuppressive
agent added, mo
Immunosuppressive
agent
PASI
before
immuno-
suppressive
agent
PASI
after
immuno-
suppressive
agent
Total survival
of ustekinumab
in months
Female 47 36.1 Methotrexate,
mycophenolate
mofetil,
hydroxyurea,
fumaric acid esters,
cyclosporine
None 20/23 0/0 12 Hydroxyurea, 500 mg
3 times a day
6.0 3 49
Male 55 25.6 Hydroxyurea,
cyclosporine,
acitretin,
methotrexate
None 17.2/16 3.6/0 14 Methotrexate, 10 mg
weekly
5.2 2.1 37
Male 32 31.5 Methotrexate,
cyclosporine
Adalimumab 14.6/11 3/5 15 Fumaric acid esters,
30 mg 3 times a
day
5.0 2.4 30
Female 64 47.5 Methotrexate Adalimumab and
infliximab
17.4/10 2.9/0 20 Methotrexate, 7.5 mg
weekly
7.6 4.2 65
Male 40 20.4 Methotrexate,
hydroxyurea,
cyclosporine
None 16.1/13 2.4/1 18 Hydroxyurea, 500 mg
twice a day
6.0 5 68
Male 47 32.2 Methotrexate,
cyclosporine,
acitretin, fumaric
acid esters
Raptiva, infliximab,
etanercept,
adalimumab
20/30 10.8/11 12 Hydroxyurea, 500 mg
3 times a day
9.4 4.7 47
Male 65 30.1 Methotrexate,
systemic 5
fluorouracil,
cyclosporine,
hydroxyurea,
fumaric acid esters,
acitretin
Etanercept, raptiva,
infliximab,
adalimumab
22.7/30 17.2/9 8 Azathioprine, 150 mg
daily
6.9 4.6 54
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Fig 1. A Kaplan-Meier plot compares our 7 patients
(current study) with those of Gniadecki et al (cohort
group).
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kinumab and the addition of an immunosuppressive
agent ranged between 8months and 20months, with
an average of 14.1 months. The range of time that
ustekinumab and the additional immunosuppressive
agent controlled the disease ranged between 37 and
68 months. The disease remains well controlled in all
patients on the combination to date except patients 6
and 7 who are discussed in detail. After performing a
nonpaired 2-tail t test, there was a significant
difference with a P value of .002 between the
Psoriasis Area and Severity Index (PASI) before and
after an immunosuppressive agent was added.
Patients 6 and 7 had more complicated outcomes.
Patient 6 did not respond to 4 biologic agents; he
started ustekinumab inOctober 2009with a PASI of 20
and DLQI 30 and initially did well for 12 months on
ustekinumab alone, then he started losing disease
control with a PASI of 7.6 andDLQI of 17. At this point,
methotrexate, 15mgweekly, was added, which led to
a decrease in PASI to 5, but the methotrexate was
stopped because of side effects. Hydroxurea, 500 mg
twice a day, initially, then 3 times a day, was used in
place of methotrexate, and this achieved disease
control with a PASI of 4.7. In April 2012, ustekinumab
was increased to 90 mg, as the patient’s weight
increased to more than 100 kg. This increase reduced
the PASI from 6.4 to 3.3. In September 2014, disease
control was lost, and enrollment in the secukinumab
trial was considered. In this patient, the addition of an
immunosuppressive agent to ustekinumab achieved
47 months of disease control.
Patient 7 also had no response to 4 biological
agents. He started ustekinumab in April 2010 with a
PASI of 22 and DLQI of 30 and up until December
2010. His disease was not under control; therefore,
fumaric acid esters were added, initially at 120 mg
daily increasing to thrice daily. At that time, the PASI
decreased from 6.3 to 0.3. In January 2012, fumaric
acid esters were stopped because of side effects, and
hydroxyurea was added. However side effects
developed, and in April 2012 azathioprine, 150 mg
daily, was added with a PASI of 6.9 and DLQI of 3.
The PASI decreased to 4.6 and the DLQI to 0. He was
doing well until June 2015 when his disease flared,
and acitretin, 25 mg daily, was added. Recently, the
patient had a transient ischemic event, and his
disease is flaring. He is now being considered for
secukinumab. In this patient, the addition of an
immunosuppressive agent to ustekinumab achieved
54 months of disease control.
DISCUSSION
In our population of patients, we found that the
addition of an immunosuppressive agent toustekinumab seemed to restore response. Patients
1 through 6 had a good response at week 16 and
subsequently efficacy dipped. At this point, an
immunosuppressive agent was added, and efficacy
was then recaptured. Because there is evidence that
the survival of a biologic depreciates year after year,
this combination could potentially prolong the sur-
vival of a biologic therapy, thereby delaying the
inevitable decrease in efficacy when one is switched
from one biologic to another.2 In patient 7, adequate
disease control was only achieved by multiple
switches between different immunosuppressive
agents. The number of switches was significantly
higher than for the rest of the patients.
Comparing our data with data from Gniadecki
et al4 shows a trend toward enhanced survival,
although this was limited by our small numbers.
Fig 1 shows a Kaplan-Meier plot comparing the time
to drug failure for patients collected from our
department labelled current study and Gniadecki’s
patients labelled cohort group.
The effectiveness of biologics in nonebiologic-
na€ıve patients is less than that of their biologic-na€ıve
counterparts.2 Explanations for this phenomenon
include: exposure to biologic agents may cause the
production of ADA, which may then adversely affect
the next biologic or differing rates of drug or
antibody catabolism and immunologic reorchestra-
tion in which suppression of a single cytokine may
induce other proinflammatory cytokines with the
redundant function.4,8
Immune complexes can form when ADAs are
present; therefore, concomitant immunosuppressive
therapy has been found to be associatedwith a lower
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treatment.9 In order to reduce ADA, the concomitant
use of immunosuppressive medications has been
used particularly in inflammatory bowel disease and
rheumatoid arthritis patients. Vermeire et al10 showed
the incidence of ADA was 44% in patients treated
with infliximab and methotrexate versus 73% in
patients treated with solely infliximab. The presence
of ADAs was associated with a shorter duration of
response in patients not taking concomitant immu-
nosuppressive medications compared with patients
taking concomitant immunosuppressive medica-
tions. This difference was not statistically significant,
and the authors felt it was because of low numbers.11
Similar results have been documented with adalimu-
mab in rheumatoid arthritis patients.10
Methotrexate has been used in combination with
biologics to prolong drug survival in patients with
rheumatoid arthritis and seems to be efficient in
reducing immunogenicity in a dose-dependent
manner with adalimumab according to Krieckaert
et al.9 Van der Heijde et al12 found statistically
significant improvements in efficacy when metho-
trexate was combined with adalimumab in rheuma-
toid arthritis patients compared with either
methotrexate or adalimumab monotherapy. The
mechanisms of this effect remain unclear; however,
it may act via an additional or synergistic effect as
well as or modulation of the immune response.10,11
Azathioprine has for some time been used in
combination with infliximab to improve the efficacy
of treatment for patients with ulcerative colitis and
Crohn’s disease. Panaccione et al13 and Lemann et al14
found that patients treated with azathioprine in addi-
tion to infliximab were more likely to remain cortico-
steroid free compared with patients who received
either azathioprine or infliximab as monotherapy.
The addition of concomitant immunosuppressive
therapymay avoid the effect of immunogenicity on the
efficacy of biologic agents. There are only 2 reports
documenting the use of additional immunosuppres-
sive agents with biologic therapies in psoriasis, but
neither of them are related to ustekinumab.15,16
None of our patients responded to systemic
immunosuppression on their own. These same
immunosuppressants were subsequently introduced
in addition to ustekinumab. We found that in most of
the cases the doses of the additional immunosup-
pressive agents tended to be smaller than the stan-
dard dose of the same agents when used in the
treatment of psoriasis.
One explanation is that the mechanism of their
action is through limiting immunogenic neutraliza-
tion of the biologic treatment and the other would be
additional immunosuppression. The choice of theadditional immunosuppressive agent depended on
the occurrence of side effects with previous expo-
sure and patient comorbidities.
The main limitations with this case series are the
small number of patients and we did not have a
control group; however, we feel that these results are
promising and warrant a multicenter study/survey.
Another limitation is that we did not measure, ADA
as this test is currently not available in our trust.CONCLUSION
Psoriasis is a chronic disease with limited treat-
ment options, and there is a need to have strategies
to prolong the longevity of treatment options.
Treatment algorithms could include, first, the addi-
tion of immunosuppressive agents as soon as effi-
cacy starts to dip or if ADAs are demonstrated in
biologic-na€ıve patients and, second, adding an
immunosuppressive agent from the start in biologic
nonna€ıve patients.
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